EP Patent

EP3936153A1 — Inhibiting ataxia telangiectasia and rad3-related protein (atr)

Assigned to Jazz Pharmaceuticals Therapeutics Inc · Expires 2022-01-12 · 4y expired

What this patent protects

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

USPTO Abstract

Novel compounds inhibiting ATR protein kinase include compounds of formula (I) disclosed herein, as well as liposome formulations comprising ATR protein kinase inhibitor compounds. The compositions are useful for the treatment of cancer.

Drugs covered by this patent

Patent Metadata

Patent number
EP3936153A1
Jurisdiction
EP
Classification
—
Expires
2022-01-12
Drug substance claim
No
Drug product claim
No
Assignee
Jazz Pharmaceuticals Therapeutics Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.